Drug intelligence / Profile preview

EK-006

Development stage: Preclinical
Lead developer: Shanghai Enkai Cell Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

EK-006 is a chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by Shanghai Enkai Cell Technology (also known as Shanghai NK Cell Technology). The therapy is engineered to target mesothelin, a cell surface glycoprotein that is highly expressed in several solid tumors, including pancreatic cancer, while showing limited expression in normal tissues. By directing T cells to express a CAR specific for mesothelin, EK-006 aims to selectively identify and eliminate mesothelin-positive malignant cells. Its primary development focus is for the treatment of pancreatic cancer.

Targets

Mesothelin

Beyond the preview

Go deeper on EK-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EK-006.

Explore the full profile